New Zealand markets close in 17 minutes

Arbutus Biopharma Corporation (ABUS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.3400-0.0800 (-2.34%)
At close: 04:00PM EDT
3.3787 +0.04 (+1.16%)
After hours: 07:51PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
12,986
18,141
39,019
10,988
6,914
-
Cost of revenue
-
-
-
-
47,481
57,601
Gross profit
-
-
-
-
-40,567
-51,590
Operating expenses
Research development
70,828
73,700
84,408
65,502
49,338
-
Selling general and administrative
22,235
22,475
17,834
17,136
14,845
-
Total operating expenses
93,063
96,175
102,242
82,638
64,183
-
Operating income or loss
-80,077
-78,034
-63,223
-71,650
-57,269
-
Interest expense
305
459
1,726
2,857
4,011
-
Total other income/expenses net
32
-44
-2,255
-1,867
-3,206
-
Income before tax
-74,385
-72,849
-65,012
-76,247
-63,745
-
Income tax expense
-
0
4,444
0
0
-
Income from continuing operations
-74,385
-72,849
-69,456
-76,247
-63,745
-
Net income
-74,385
-72,849
-69,456
-76,247
-63,745
-
Net income available to common shareholders
-74,385
-72,849
-69,456
-88,386
-75,868
-
Basic EPS
-0.46
-
-0.46
-0.83
-1.00
-2.89
Diluted EPS
-0.46
-
-0.46
-0.83
-1.00
-2.89
Basic average shares
162,714
-
150,939
106,242
75,835
57,093
Diluted average shares
162,714
-
150,939
106,242
75,835
57,093